CXCL10 expression and prognostic significance in stage II and III colorectal cancer

Molecular Biology Reports

Volumn 37, Issue 6, 2010, Pages 3029-3036

  Jiang, Zheng ^a   Xu, Ye ^a   Cai, Sanjun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CXCL10; Prognosis; Stage II and III colorectal cancer

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA; CXCL10 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL STRAIN CACO 2; CELL STRAIN HCT116; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; FROZEN SECTION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; TUMOR CELL LINE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHEMOKINE CXCL10; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; KAPLAN-MEIER ESTIMATE;

EID: 77955659643     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-009-9873-z     Document Type: Article

References (37)

1. J Weitz M Koch J Debus T Höhler PR Galle MW Büchler 2005 Colorectal cancer Lancet 365 153 165 10.1016/S0140-6736(05)17706-X 15639298 (Pubitemid 40091806)
2. G Cserni 2003 Nodal staging of colorectal carcinomas and sentinel nodes J Clin Pathol 56 327 335 10.1136/jcp.56.5.327 1:STN:280:DC%2BD3s7pvFOitg%3D%3D 12719450 (Pubitemid 36566815)
3. A de Gramont C Tournigand T André AK Larsen C Louvet 2007 Adjuvant therapy of stage II and III colon cancer Semin Oncol 34 S37 S40 10.1053/j.seminoncol.2007.01.004 17449351 (Pubitemid 46590359)
4. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF 16355210 (Pubitemid 43093958)
5. UP Singh S Singh N Iqbal CT Weaver JR McGhee JW Lillard Jr 2003 IFN-g-inducible chemokines enhance adaptive immunity and colitis J Interferon Cytokine Res 23 591 600 10.1089/107999003322485099 1:CAS:528: DC%2BD3sXot1anur0%3D 14585199 (Pubitemid 37323681)
6. E Lazzeri P Romagnani 2005 CXCR3-binding chemokines: novel multifunctional therapeutic targets Curr Drug Targets Immune Endocr Metab Disord 5 109 118 10.2174/1568008053174723 1:CAS:528:DC%2BD2MXisVKktLc%3D (Pubitemid 40394308)
7. C Sgadari AL Angiolillo BW Cherney SE Pike JM Farber LG Koniaris P Vanguri PR Burd N Sheikh G Gupta J Teruya-Feldstein G Tosato 1996 Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo Proc Natl Acad Sci USA 93 13791 13796 10.1073/pnas.93.24.13791 1:STN:280:DyaK2s%2FpvVCktg%3D%3D 8943014 (Pubitemid 26424199)
8. C Kanegane C Sgadari H Kanegane J Teruya-Feldstein L Yao G Gupta JM Farber F Liao L Liu G Tosato 1998 Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12 J Leukoc Biol 64 384 392 1:CAS:528:DyaK1cXmtVOls7c%3D 9738666
9. E Sato J Fujimoto H Toyoki H Sakaguchi SM Alam I Jahan T Tamaya 2007 Expression of IP-10 related to angiogenesis in uterine cervical cancers Br J Cancer 96 1735 1739 10.1038/sj.bjc.6603790 1:CAS:528:DC%2BD2sXlvVShtrs%3D 17505511 (Pubitemid 46847211)
10. A Biragyn K Tani MC Grimm S Weeks LW Kwak 1999 Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity Nat Biotechnol 17 253 258 10.1038/6995 1:CAS:528: DyaK1MXhs1Chsbo%3D 10096292 (Pubitemid 29122633)
11. I Narvaiza G Mazzolini M Barajas M Duarte M Zaratiegui C Qian I Melero J Prieto 2000 Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy J Immunol 164 3112 3122 1:CAS:528: DC%2BD3cXhvVeksrs%3D 10706701
12. AL Feldman J Friedl TE Lans SK Libutti D Lorang MS Miller EM Turner SM Hewitt HR Alexander 2002 Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts Int J Cancer 99 149 153 10.1002/ijc.10292 1:CAS:528:DC%2BD38XivVCgsLw%3D 11948506 (Pubitemid 34273212)
13. SV Maru KA Holloway G Flynn CL Lancashire AJ Loughlin DK Male IA Romero 2008 Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation J Neuroimmunol 199 35 45 10.1016/j.jneuroim.2008.04.029 1:CAS:528:DC%2BD1cXptVWqtrk%3D 18538864
14. D Datta JA Flaxenburg S Laxmanan C Geehan M Grimm AM Waaga-Gasser DM Briscoe S Pal 2006 Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer Cancer Res 66 9509 9518 10.1158/0008-5472.CAN-05-4345 1:CAS:528:DC%2BD28XhtVamsrbE 17018607 (Pubitemid 44623649)
15. NA Giese Z Raykov L DeMartino A Vecchi S Sozzani C Dinsart JJ Cornelis J Rommelaere 2002 Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice Cancer Gene Ther 9 432 442 10.1038/sj.cgt.7700457 1:CAS:528:DC%2BD38XjsVSmtrk%3D 11961666
16. J Keyser J Schultz K Ladell L Elzaouk L Heinzerling J Pavlovic K Moelling 2004 IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency Exp Dermatol 13 380 390 10.1111/j.0906-6705.2004.00191.x 1:CAS:528:DC%2BD2cXmtFyit70%3D 15186325 (Pubitemid 38868211)
17. KL Reckamp RA Figlin N Moldawer AJ Pantuck AS Belldegrun MD Burdick RM Strieter 2007 Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy J Immunother 30 417 424 10.1097/CJI.0b013e31802e089a 1:CAS:528:DC%2BD2sXksFOlsbY%3D 17457216 (Pubitemid 46684431)
18. SK Mendiratta A Quezada M Matar NM Thull JS Bishop JL Nordstrom F Pericle 2000 Combination of interleukin 12 and interferon a gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma Hum Gene Ther 11 1851 1862 10.1089/10430340050129477 1:CAS:528:DC%2BD3cXmtlenu7k%3D 10986558
19. C Zilocchi A Stoppacciaro C Chiodoni M Parenza N Terrazzini MP Colombo 1998 Interferon g-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and granulocyte/macrophage colony-stimulating factor J Exp Med 188 133 143 10.1084/jem.188.1.133 1:CAS:528:DyaK1cXksFOhu7w%3D 9653090 (Pubitemid 28328612)
20. G Li L Tian JM Hou ZY Ding QM He P Feng YJ Wen F Xiao B Yao R Zhang F Peng Y Jiang F Luo X Zhao L Zhang Q Zhou YQ Wei 2005 Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors Clin Cancer Res 11 4217 4224 10.1158/1078-0432.CCR-04-2117 1:CAS:528:DC%2BD2MXks1GksLk%3D 15930360 (Pubitemid 40791588)
21. L Yao SE Pike J Setsuda J Parekh G Gupta M Raffeld ES Jaffe G Tosato 2000 Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12 Blood 6 1900 1905
22. A Zipin-Roitman T Meshel O Sagi-Assif B Shalmon C Avivi RM Pfeffer IP Witz A Ben-Baruch 2007 CXCL10 promotes invasion related properties in human colorectal carcinoma cells Cancer Res 67 3396 3405 10.1158/0008-5472.CAN-06-3087 1:CAS:528:DC%2BD2sXksVGksb8%3D 17409450 (Pubitemid 46724880)
23. E Naschberger RS Croner S Merkel A Dimmler P Tripal KU Amann E Kremmer WM Brueckl T Papadopoulos C Hohenadl W Hohenberger M Stürzl 2008 Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy Int J Cancer 123 2120 2129 10.1002/ijc.23764 1:CAS:528:DC%2BD1cXht1Chs7jO 18697200
24. MM Bertagnolli 2007 Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back Lancet Oncol 8 439 443 10.1016/S1470-2045(07)70139-0 1:CAS:528:DC%2BD2sXkslKru7g%3D 17466901 (Pubitemid 46621772)
25. LM Coussens Z Werb 2002 Inflammation and cancer Nature 420 860 867 10.1038/nature01322 1:CAS:528:DC%2BD38XpsFygtb4%3D 12490959 (Pubitemid 36019639)
26. A Albini MB Sporn 2007 The tumour microenvironment as a target for chemoprevention Nat Rev Cancer 7 139 147 10.1038/nrc2067 1:CAS:528: DC%2BD2sXotFOjuw%3D%3D 17218951
27. KE de Visser A Eichten LM Coussens 2006 Paradoxical roles of the immune system during cancer development Nat Rev Cancer 6 24 37 10.1038/nrc1782 16397525 (Pubitemid 43053650)
28. FR Greten L Eckmann TF Greten JM Park ZW Li LJ Egan MF Kagnoff M Karin 2004 IKK beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer Cell 118 285 296 10.1016/j.cell.2004.07.013 1:CAS:528:DC%2BD2cXmslKrs7o%3D 15294155 (Pubitemid 39061110)
29. D Pardoll 2001 T cells and tumours Nature 411 1010 1012 10.1038/35082676 1:CAS:528:DC%2BD3MXltVCltbY%3D 11429587
30. JW Pollard 2004 Tumour-educated macrophages promote tumour progression and metastasis Nat Rev Cancer 4 71 78 10.1038/nrc1256 1:CAS:528: DC%2BD2cXos12qtA%3D%3D 14708027
31. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D 4938153
32. J Folkman 2006 Angiogenesis Annu Rev Med 57 1 18 10.1146/annurev.med.57. 121304.131306 1:CAS:528:DC%2BD28Xis1Cksrg%3D 16409133 (Pubitemid 43261975)
33. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
34. E Sato J Fujimoto H Toyoki H Sakaguchi SM Alam I Jahan T Tamaya 2007 Expression of IP-10 related to angiogenesis in uterine cervical cancers Br J Cancer 96 1735 1739 10.1038/sj.bjc.6603790 1:CAS:528:DC%2BD2sXlvVShtrs%3D 17505511 (Pubitemid 46847211)
35. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (2002) AJCC cancer staging manual, 6th edn. Springer, New York
36. T Trarbach S Kubicka U Hacker K Ridwelski A Reinacher-Schick 2008 Adjuvant therapy of colon carcinoma Onkologie 31 19 23 10.1159/000163072 19033700
37. S De Dosso C Sessa P Saletti 2009 Adjuvant therapy for colon cancer: present and perspectives Cancer Treat Rev 35 160 166 10.1016/j.ctrv.2008.10.001 19013023